<DOC>
	<DOCNO>NCT01377987</DOCNO>
	<brief_summary>The ultimate goal improve understand pathophysiology resistance effective treatment sleep disorder breathe patient heart failure , focus select patient benefit specifically acetazolamide treatment . The study address three primary hypothesis : 1 ) Acetazolamide treatment reduce apnea-hypopnea index improve marker heart-failure severity heart-failure patient sleep apnea . 2 ) Acetazolamide provide great improvement patient severe ventilatory control instability ( strong chemoreflex response carbon dioxide ; high loop gain ) . 3 ) Acetazolamide act primarily via stabilize ventilatory control ( reduce loop gain ) , rather via improvement upper airway anatomy , pulmonary congestion , cardiac function .</brief_summary>
	<brief_title>Predicting Successful Sleep Apnea Treatment With Acetazolamide Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<criteria>Inclusion Criteria ( Heart failure patient ) Left ventricular ejection fraction ( EF ) &lt; 50 % , heart failure preserve EF Age 1889 Inclusion Criteria ( Controls ) No history evidence heart failure Age 1889 severe obstructive respiratory disease unstable heart failure status recent use positive airway pressure therapy current use opioids , benzodiazepine severe kidney disease severe anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>